Prasugrel

Type: Product
Name: Prasugrel
First reported 2 hours ago - Updated 2 hours ago - 1 reports

House Calls: What to know about using blood thinners

House Calls runs every two weeks. Today’s column is written by Christopher B. Cutter, a physician at Sutter Coast Community Clinic.Physicians are using various types of blood thinners with increasing regularity to prevent serious disease.In the last decade ... [Published Daily Triplicate - 2 hours ago]
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

Bivalirudin Bleeding? More from NAPLES III, BRAVE 4, BRIGHT

WASHINGTON, DC — There are mounting questions over whether bivalirudin (Angiomax, the Medicines Company) does indeed reduce major bleeding in the setting of contemporary primary PCI, compared with unfractionated heparin (UFH), without routine GPIIb/IIIa ... [Published General Medicine eJournal - Apr 04 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

Point of care platelet activity measurement in primary PCI [PINPOINT-PPCI]: a protocol paper

Study protocolThomas W Johnson , Debbie Marsden , Andrew Mumford , Katie Pike , Stuart Mundell , Mark Butler , Julian W Strange , Ruth Bowles , Chris Rogers , Andreas Baumbach and Barnaby C ReevesBMC Cardiovascular Disorders 2014, 14 :44doi:10.1186/1 ... [Published BMC - Apr 04 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

Coronary Heart Disease Medications

Medical Editor:What are the different types of coronary heart disease medicines?Many different types of medications are used to treatcoronary heart disease ,also called coronary artery disease, depending on the patient's needs. You maybe prescribed antiplatelet ... [Published RxList - Apr 03 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

CME Symposium: Optimizing Risk Reduction in the Acute Coronary Syndrome Patient

1 2 NCNP 2014NCNP 2014 - Apr. 1, 2014 - CHICAGO -- Optimizing Risk Reduction in the Acute Coronary Syndrome Patient: Facing the ChallengesFacultyLynne Braun, PhD, CNP, FAHA, FAAN (Chair)Professor of NursingRush University College of NursingChicago, I ... [Published Prlog - Apr 01 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Acute coronary syndrome - prasugrel with PCI (review TA182): Appraisal consultation

First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

Medical management after control of myocardial ischaemia

After recovery from myocardial infarction, patients should receive aspirin and statin therapy and be evaluated regarding their need for coronary revascularisation, additional pharmacological treatment and possible device therapy.Key PointsA large evidence ... [Published Medicine Today - Mar 27 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Daiichi Sankyo reports encouraging data from acute coronary syndrome analysis

In this subgroup analysis, the relationship between PRU at 5-12 hours after LD and the incidence of MACE within three days after PCI was evaluated. By evaluating the correlation between PRU and MACE, the cutoff value (PRU=262) to predict the prevention ... [Published Individual.com - Mar 25 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 1 reports

Daiichi Sankyo receives approval in Japan for manufacturing and marketing of the antiplatelet agent Efient® 3.75mg/5mg tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has received approval from the Ministry of Health, Labour and Welfare in Japan for the antiplatelet agent Efient® 3.75mg/5mg Tablets (JAN: Prasugrel Hydrochloride) for ... [Published European Pharmaceutical Review - Mar 24 2014]
First reported Mar 18 2014 - Updated Mar 18 2014 - 1 reports

Personalized Medicine Study for Heart Attack Patients Begins in Germany

Rapid CYP2C19 Testing for Personalized Antiplatelet Therapy in 600-Patient Clinical Trial with Spartan Bioscience Spartan Bioscience today announced the start of a 600-patient study of personalized medicine for cardiac stent patients in Germany. The study ... [Published PRWeb - Mar 18 2014]
First reported Feb 17 2014 - Updated Feb 19 2014 - 1 reports

Human medicines European public assessment report (EPAR): Efient, prasugrel, Revision: 9, Authorised

Entities: EFIENT, Prasugrel
First reported Feb 01 2014 - Updated Feb 01 2014 - 1 reports

Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes

Quotes

"There were not a lot of randomized controlled trials designed to address this," he noted. "In clinical practice, it's always a question of whether bivalirudin has the same magnitude of benefit [seen in the acute MI trials] in stable IHD or NSTE-ACS patients, in terms of the reduction"
...M D , Ph D , cardiologist and associate professor, Erasmus University Medical Center in the Netherlands , and lead investigator of the study. "For the first time, we have handled a drug-eluting stent as we would a bare metal stent in terms of the duration and intensity of anti-platelet therapy and have still shown the superior safety and efficacy of the drug-eluting stent."
...operators at his institution are primarily using heparin, not bivalirudin, although they've only just stopped randomizing patients into BRAVE 4. "We are more comfortable with the lower doses of heparin based on ISAR REACT 3A " he noted. Byrne and his colleagues are also already enrolling
Infringement of certain of U S Patent Nos. 5,288,726 ( "Tetrahydrothienopyridine Derivatives, Furo and Pyrrolo Analogs Thereof and Their Preparation and Uses for Inhibiting Blood Platelet Aggregation" issued February 22, 1994), 8,404,703 ("Medicinal Compositions Containing Aspirin," issued March 26, 2013) and 8,569,325 ("Method of Treatment with C...

More Content

All (26) | News (21) | Reports (0) | Blogs (5) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
House Calls: What to know about using blood thi... [Published Daily Triplicate - 2 hours ago]
Preparing for coronary artery bypass surgery [Published Examiner.com - Apr 20 2014]
Bivalirudin Cuts Bleeds in NSTE-ACS, Stable Pat... [Published General Medicine eJournal - Apr 17 2014]
Top medicine articles for April 2014 [Published Clinical Cases and Images: CasesBlog - Apr 17 2014]
GlycoMimetics: A Promising Sickle Cell Disease ... [Published Seeking Alpha - Apr 10 2014]
Drug-eluting stents demonstrate better outcomes... [Published HispanicBusiness.com - Apr 10 2014]
Bivalirudin Bleeding? More from NAPLES III, BRA... [Published General Medicine eJournal - Apr 04 2014]
Point of care platelet activity measurement in ... [Published BMC - Apr 04 2014]
BRAVE-4 and HEAT-PPCI: Bivalirudin Takes a Hit [Published General Medicine eJournal - Apr 03 2014]
Coronary Heart Disease Medications [Published RxList - Apr 03 2014]
CME Symposium: Optimizing Risk Reduction in the... [Published Prlog - Apr 01 2014]
Acute coronary syndrome - prasugrel with PCI (r... [Published NICE | National Institute for Health and Clinic ... - Apr 01 2014]
Drug-eluting stents demonstrate better outcomes... [Published EurekAlert! - Mar 31 2014]
Medical management after control of myocardial ... [Published Medicine Today - Mar 27 2014]
Daiichi Sankyo reports encouraging data from ac... [Published Individual.com - Mar 25 2014]
Daiichi Sankyo receives approval in Japan for m... [Published European Pharmaceutical Review - Mar 24 2014]
Court Report [Published JD Supra - Mar 18 2014]
Personalized Medicine Study for Heart Attack Pa... [Published PRWeb - Mar 18 2014]
Snowball Effect: The Incidence of Premature Par... [Published FDA Law Blog - Mar 17 2014]
Lilly Sues Dr. Reddy's, 34 Others For Effient P... [Published Health News Daily - Mar 14 2014]
Spartan Bioscience Announces Collaboration With... [Published PRWeb - Mar 05 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 17 2014]
Product Positioning 2.0 [Published Pharmaceutical Executive - Feb 05 2014]
Pretreatment with Prasugrel in Non–ST-Segment E... [Published NEJM Most Cited Articles - Recent - Feb 01 2014]
Personalized Medicine Study for Heart Attack Pa... [Published PRWeb - Dec 12 2013]
The Medicines Company's phase IIIb EUROMAX tria... [Published PharmaBiz - Nov 01 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Top medicine articles for April 2014 [Published Clinical Cases and Images: CasesBlog - Apr 17 2014]
A collection of some interesting medical articles published recently:Noninfluenza Vaccination Rates Among U.S. Adults Remain Low - only 16% for Tdap in 2012 http://buff.ly/NcduqD Adult Tonsillectomy Shown to Be Safe: 30-day mortality rate was low, ...
Acute coronary syndrome - prasugrel with PCI (r... [Published NICE | National Institute for Health and Clinic ... - Apr 01 2014]
Snowball Effect: The Incidence of Premature Par... [Published FDA Law Blog - Mar 17 2014]
By Kurt R. Karst –It was just a little more than three months ago that we blogged on the topic of “premature notice” in the context of a Complaint filed by Otsuka Pharmaceutical Co., Ltd. (“Otsuka”) against Par Pharmaceutical, Inc. (“Par”) concerning ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Feb 17 2014]
Pretreatment with Prasugrel in Non–ST-Segment E... [Published NEJM Most Cited Articles - Recent - Feb 01 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.